PMID- 29465586
OWN - NLM
STAT- MEDLINE
DCOM- 20180302
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 8
DP  - 2018 Feb
TI  - YiQiFuMai injection for chronic heart failure: Protocol for a systematic review 
      and meta-analysis.
PG  - e9957
LID - 10.1097/MD.0000000000009957 [doi]
LID - e9957
AB  - BACKGROUND: Chronic heart AQ4 failure (CHF) is the final stage of various heart 
      diseases. YiQiFuMai injection (YQFMI) has been widely applied in the treatment of 
      CHF. However, to our knowledge, there has been no systematic review or 
      meta-analysis of randomized controlled trails (RCTs) regarding the effectiveness 
      of this treatment. Here, we provide a protocol to evaluate the efficacy and 
      safety of YQFMI for CHF. METHODS: To evaluate the clinical efficacy of YQFMI in 
      treating CHF, 2 researcher members will independently search the RCTs in the 
      following 8 Chinese and English databases, in which the data collection will be 
      from the time when the respective databases were established to January 2018. The 
      databases will include MEDLINE, EMBASE, Cochrane CENTRAL, CINAHL, the Chinese 
      Biomedical Literature Database, the China National Knowledge Infrastructure, VIP 
      Information and Wanfang Data. The therapeutic effects according to the mortality 
      and the New York Heart Association (NYHA) function classification will be 
      accepted as the primary outcomes. We will use RevMan V.5.3 software as well to 
      compute the data synthesis carefully when a meta-analysis is allowed. RESULTS: 
      This study will provide a high-quality synthesis of current evidence of YQFMI for 
      CHF from several aspects including mortality, NYHA function classification. 
      CONCLUSION: The conclusion of our systematic review will provide evidence to 
      judge whether YQFMI is an effective intervention for CHF.PROSPERO registration 
      number: PROSPERO CRD42017079696.
FAU - Wang, Yuanping
AU  - Wang Y
AD  - The Second Clinical College of Guangzhou University of Chinese Medicine, 
      Guangzhou Shunde Hospital Affiliated of Guangzhou University of Chinese Medicine, 
      Shunde, China.
FAU - Li, Xiaohui
AU  - Li X
FAU - Li, Ziqing
AU  - Li Z
FAU - Zhang, Yu
AU  - Zhang Y
FAU - Wang, Dawei
AU  - Wang D
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (yi-qi-fu-mai)
SB  - IM
MH  - Adult
MH  - Cardiotonic Agents/*administration & dosage
MH  - Chronic Disease
MH  - Clinical Protocols
MH  - Drugs, Chinese Herbal/*administration & dosage
MH  - Female
MH  - Heart Failure/*drug therapy
MH  - Humans
MH  - Injections
MH  - Male
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC5842014
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2018/02/22 06:00
MHDA- 2018/03/03 06:00
PMCR- 2018/02/23
CRDT- 2018/02/22 06:00
PHST- 2018/02/22 06:00 [entrez]
PHST- 2018/02/22 06:00 [pubmed]
PHST- 2018/03/03 06:00 [medline]
PHST- 2018/02/23 00:00 [pmc-release]
AID - 00005792-201802230-00051 [pii]
AID - MD-D-17-07810 [pii]
AID - 10.1097/MD.0000000000009957 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Feb;97(8):e9957. doi: 10.1097/MD.0000000000009957.